X-linked Agammaglobulinemia
7
0
2
2
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 55/100
28.6%
2 terminated out of 7 trials
50.0%
-36.5% vs benchmark
29%
2 trials in Phase 3/4
100%
2 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (7)
Immune Disorder HSCT Protocol
COVID-19 Vaccine Responses in PIDD Subjects
Assessment of Immunogenicity of Zostavax® in Patients With Antibody Deficiency 60 Years of Age and Older
A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency
Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy
Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies
Study of Genetic and Molecular Defects in Primary Immunodeficiency Disorders